SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Grayscale Bitcoin Mini Trust ETF - Common units of fractional undivided beneficial interest

Grayscale Bitcoin Mini Trust ETF

GBTC is trending as Bitcoin flirts with all-time highs, driving discussion about potential breakouts and future price targets. Community members are closely watching technical indicators and whale activity, anticipating a continued uptrend. Broader market factors, like potential shifts from gold to Bitcoin and the impact of government policies, are also being considered.

The SolyCat is a symbol of energy and mystery. Shining like the sun and agile as a feline.  Solycat is here to take over Solana! Inspired by Shiba Inu’s legendary rise on Ethereum, Solycat is the ultimate meme coin designed for Solana’s fast and scalable blockchain.  Our mission is simple: become the top cat of Solana. With bold branding, a vibrant community, and unstoppable momentum, Solycat is ready to dominate. This isn’t just another token—it’s a movement powered by fun, creativity, and the spirit of decentralization.  Join the pride and let’s make history, one paw at a time!

Solycat

Solycat is gaining attention, with community members highlighting its recent launch on Phantom Wallet and potential for significant growth. The conversation revolves around 'moon' and 'rocket' references suggesting possible rapid price appreciation. Some users are pointing out potential scam risks.

Moo Deng

MOODENG is trending as traders discuss recent price volatility and potential for a breakout. Community members are debating entry points, with some pointing to technical analysis patterns, while others express skepticism, citing its meme coin status and past performance. The coin's listing on Robinhood and upcoming birthday are also being mentioned as potential catalysts.

Syndax Pharmaceuticals, Inc. engages in the development of cancer therapies. Its products include SyndAccess, Revuforj, Niktimvo, and IncyteCARES. The company was founded by Richard A. Heyman, Eckard Weber, Peter Ordentlich, Ronald M. Evans and Michael Downes on October 11, 2005 and is headquartered in New York, NY.

Syndax Pharmaceuticals Inc

Syndax Pharmaceuticals is trending following FDA approval of their leukemia drug, Revuforj, though a boxed warning regarding potentially fatal side effects tempers initial enthusiasm. The community is debating the impact of the safety label, comparing it to competitor Kura Oncology's profile, and weighing whether the market is overreacting given the drug's efficacy and the unmet need it addresses. Some believe the dip is a buying opportunity, while others worry about potential risks and side effects.

Innodata, Inc. is a data engineering company, which engages in providing artificial intelligence software platforms and management of its services. It operates through the following business segments: Digital Data Solutions (DDS), Synodex, and Agility. The DDS segment combines deep neural networks and human expertise in multiple domains to make unstructured information useable. The Synodex segment enables clients in the insurance and healthcare sectors to transform medical records into useable digital data and to apply technologies to the digital data to augment decision support. The Agility segment provides tools and related professional services that enable public relations and communications professionals to discover influencers, amplify messages, monitor coverage, and measure the impact of campaigns. The company was founded by Todd H. Solomon in 1988 and is headquartered in Ridgefield Park, NJ.

Innodata Inc

Innodata is trending as investors anticipate potential new contracts following its Gen AI Summit, where over 300 AI executives were in attendance. The community speculates about a possible TikTok deal and expansion into government contracts, driving institutional interest. Bullish sentiment is fueled by analysts increasing price targets, though some caution against excessive speculation and highlight the company's AI-driven growth amid rising competition.

Tonix Pharmaceuticals Holding Corp. is a clinical-stage biopharmaceutical company, which focuses on the discovery, acquisition, and development of small molecules and biologics to treat and prevent human disease and alleviate suffering. Its portfolio includes TNX-102 SL, TNX-601, TNX-801, and TNX-1800. The company was founded by Seth Lederman and Donald W. Landry on November 16, 2007 and is headquartered in Chatham, NJ.

Tonix Pharmaceuticals Holding Corp

TNXP is trending as the stock price continues to drop post FDA approval, leading to discussions around management, dilution, and future prospects. The community is debating whether the current price represents a buying opportunity or reflects deeper issues with the company's leadership and commercialization strategy. Some traders are noting potential short squeeze setups due to high short interest.

ADMA Biologics, Inc. operates as a biopharmaceutical company, which is engaged in manufacturing, marketing, and developing specialty plasma-derived biologics. The firm operates through the following business segments: ADMA BioManufacturing, Plasma Collection Center, and Corporate. The ADMA BioManufacturing segment consists of immune globulin manufacturing and development operations. The Plasma Collection Center consists of source plasma collection facilities. The Corporate segment includes general and administrative overhead expenses. The company was founded by Adam S. Grossman and Jerrold B. Grossman on June 24, 2004 and is headquartered in Ramsey, NJ.

Adma Biologics Inc

ADMA Biologics is trending amid discussions about a potential recall of specific lots and the impact on revenue, with community members analyzing the company's response and comparing it to similar situations with competitors. Some traders are interpreting recent stock sales by the CEO, alongside an FDA safety notice, while others suggest potential manufacturing issues. Despite concerns, many community members express confidence in the company's long-term growth and potential for a buyback.

Tidal Trust II - YieldMax Ultra Option Income Strategy ETF

YieldMax Ultra Option Income Strategy ETF

ULTY is trending as investors discuss dividend payouts, NAV erosion, and overall profitability; some express concern over the fund's long-term viability. Community members are weighing strategies like reinvesting dividends versus taking profits, with some considering alternative high-yield ETFs.  Broader discussions include the impact of market volatility and potential reverse splits.

Inhibrx Biosciences, Inc. is a clinical-stage biopharmaceutical company, which includes a pipeline of novel biologic therapeutic candidates, developed using proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize multivalent formats where the precise valency can be optimized in a target-centric way to mediate what is believed to be the most appropriate agonist function. The company was founded by Brendan P. Eckelman on January 8, 2024 and is headquartered in La Jolla, CA.

Inhibrx Biosciences Inc.

Inhibrx Inc

Inhibrx ($INBX) is trending due to positive updates on its INBRX-101 drug for AATD, specifically regarding a functional alpha-1 antitrypsin serum levels endpoint, leading to speculation about accelerated FDA approval; the community is actively discussing its potential and analyst target price increase. Some traders are noting its low float and potential for a short squeeze, while others are wary of a possible upcoming offering.

International Business Machines Corp. is an information technology company, which engages in the provision of integrated solutions that leverage information technology and knowledge of business processes. It operates through the following segments: Software, Consulting, Infrastructure, Financing, and Other. The Software segment combines hybrid cloud platform and software solutions to help clients become more data-driven, and to automate, secure, and modernize their environments. The Consulting segment focuses on integrating skills on strategy, experience, technology and operations by domain and industry. The Infrastructure segment offers solutions for hybrid cloud and is the foundation of the hybrid cloud stack. Infrastructure is optimized for infusing AI into mission-critical transactions and tightly integrated with IBM Software including Red Hat for accelerated hybrid cloud benefits. The Financing segment refers to the client and commercial financing, facilitating IBM clients’ acquisition of IT systems, software, and services. The company was founded by Charles Ranlett Flint and Thomas J. Watson Sr. on June 16, 1911 and is headquartered in Armonk, NY.

International Business Machines Corp.

IBM is trending due to advancements in quantum computing, including a partnership leveraging AMD chips for error correction, which has driven its largest single-day stock surge since January; community discussions highlight IBM's potential leadership in quantum and AI. While reactions to recent earnings have been mixed, some see the stock as undervalued, with potential upside driven by its hybrid cloud and AI initiatives.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Nu Skin Enterprises to Announce Third Quarter 2025 Financial Results

Nu Skin Enterprises, Inc. (NYSE: NUS) today announced it will release third quarter 2025 results after the market closes on Thursday, Nov. 6. The Nu Skin management team will host a conference call...

Strength Seen in Nu Skin (NUS): Can Its 6.2% Jump Turn into More Strength?

Nu Skin (NUS) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Coty (COTY) Up 12.1% Since Last Earnings Report: Can It Continue?

Coty (COTY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Shares of Nu Skin Enterprises Inc. ($NUS) surged more than 24% in after-hours trading on Thursday after the company’s better-than-expected fourth-quarter earnings, lifting retail sentiment.Nu Skin Q4 earnings per share came in at $0.38, beating consensus estimates of $0.22, while revenues stood at $445.55 million, surpassing estimates of $436.05 million, according to Stocktwits data.Its board declared a quarterly cash dividend of $0.06 per share, which will be paid on March 5, 2025, to shareholders of record on Feb. 24, 2025.“We were pleased to beat our fourth quarter revenue guidance, generate sequential revenue growth and exceed our adjusted earnings as we materially completed our restructuring plan," said Ryan Napierski, Nu Skin president and CEO. “As we look ahead to 2025, we anticipate improving business trends and a return to year-over-year growth in several of our markets but also anticipate continued economic challenges and poor consumer sentiment, particularly in Greater China and South Korea.Nu Skin plans to focus on strengthening its core business with the rollout of its sales performance compensation plan in several markets and accelerating growth in developing markets including Latin America, added Napierski.For 2025, its annual revenue guidance is $1.48 to $1.62 billion, with about 3% of foreign currency headwind. That is below the $1.7 billion expected by analysts, according to Fly.com.The company expects adjusted EPS to be $0.90 to $1.30, excluding the gain from the sale of Mavely. That compares to consensus estimates of $0.76.Sentiment on Stocktwits improved to ‘extremely bullish’ from ‘bearish’ a week ago. Message volumes climbed to the ‘high’ territory from ‘low.’<figure class="image"><img style="aspect-ratio:1324/302;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/Screenshot_2025_02_14_at_6_37_05_AM_6dbe77d445.png" alt="Screenshot 2025-02-14 at 6.37.05 AM.png" width="1324" height="302"><figcaption>NUS sentiment meter and message volumes on Feb 13</figcaption></figure><stembedurl>https://stocktwits.com/fer69/message/604222159</stembedurl>Nu Skin Enterprises, focused on beauty and wellness, operates Nu Skin and Rhyz Inc., operating in nearly 50 markets worldwide.Nu Skin stock is down 6.8% year-to-date.For updates and corrections, email newsroom[at]stocktwits[dot]com.

(Photo Illustration by Igor Golovniov/SOPA Images/LightRocket via Getty Images)

Nu Skin Stock Surges After-Hours On Strong Q4 Performance: Retail Cheers

For 2025, its annual revenue guidance is $1.48 to $1.62 billion, with about 3% of foreign currency headwind.

Equity

Nu Skin Enterprises Reports Fourth Quarter and Full-year 2024 Results Above Company Revenue Guidance

Nu Skin Enterprises Inc. (NYSE: NUS) today announced fourth quarter and full-year 2024 results above its latest revenue guidance. Executive Summary Q4 2024 vs. Prior-year Quarter Revenue $445.6...

Nu Skin Enterprises Announces Quarterly Dividend

Nu Skin Enterprises, Inc. (NYSE: NUS) today announced its board of directors has declared a quarterly cash dividend of $0.06 per share, which will be paid on March 5, 2025, to shareholders of record...

Nu Skin Enterprises Announces Q4 Preliminary Revenue at High End of Guidance

Nu Skin Enterprises Inc. (NYSE: NUS) today announced Q4 2024 preliminary revenue at the high end of the companys guidance range ahead of its presentation at the ICR Conference on Tuesday, Jan. 14...

Futures Rebound After Longest Losing Streak Since April

Futures Rebound After Longest Losing Streak Since April

 US equity futures posted modest gains suggesting stocks may finally halt a five-day losing streak, the longest since April...

Nu Skin Enterprises Announces Strategic Transaction of Mavely for $250 Million

Nu Skin Enterprises Inc. (NYSE: NUS) today announced that its Rhyz Inc. subsidiary completed a strategic transaction with Later, a portfolio company of Summit Partners. As part of the transaction...

Later Acquires Mavely for $250 Million, Unlocking New Opportunities for Marketers and Creators to Maximize their Return on Social

Later Acquires Mavely for $250 Million, Unlocking New Opportunities for Marketers and Creators to Maximize their Return on Social Later Acquires Mavely for $250 Million, Unlocking New Opportunities...

Nu Skin Enterprises, Inc. is a holding company, which engages in the development and distribution of beauty and wellness solutions. It operates through the following segments: Mainland China, Americas, South Korea, Southeast Asia/Pacific, EMEA, Japan, Hong Kong/Taiwan, Nu Skin Other, Manufacturing, and Rhyz Other. The company was founded by Blake M. Roney, Sandra N. Tillotson, and Steven J. Lund in 1984 and is headquartered in Provo, UT.

Nu Skin Enterprises, Inc. - Ordinary Shares - Class A

Cut 25 bps

Cut 50+ bps

No change

What will the Fed decide at its October meeting? Polymarket gives a 92% chance of a 25 bps cut. 
 
*Powered by Polymarket

Current Price	N/A
Prev Close	N/A
Open	N/A
Dividend Yield	3.48%
50-Day Moving Average	$11.61
Beta	0.95
Avg. Volume	641,228.19
PE Ratio	5.50

52-Week High	$14.62
52-Week Low	$5.32
Market Capitalization	$545.46M
EPS (Annual)	-$2.95
Price to Book	0.69
Revenue Per Employee	$153,281.77
Enterprise Value/EBITDA	N/A

NUS
Nu Skin Enterprises, Inc. - Ordinary Shares - Class A

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest NUS News

NUSNu Skin Enterprises, Inc. - Ordinary Shares - Class A